Drug
Exatecan
Exatecan: highest development phase Phase 3, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| exatecan mesylate NCT00023972 | Phase 3 | Pancreatic Cancer |
Latest
No recent events.
Follow Exatecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.